CoChat

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

Open access
MEASE, PHILIP J., WEI, NATHAN, FUDMAN, EDWARD J., KIVITZ, ALAN J., SCHECHTMAN, JOY, TRAPP, ROBERT G., HOBBS, KATHRYN F., GREENWALD, MARIA, HOU, ANTONY, BOOKBINDER, STEPHEN A., GRAHAM, GALEN E., WIESENHUTTER, CRAIG W., WILLIS, LARRY, RUDERMAN, ERIC M., FORSTOT, JOSEPH Z., MARICIC, MICHAEL J., DAO, KATHRYN H., PRITCHARD, CHARLES H., FISKE, DARRELL N., BURCH, FRANCIS X., PRUPAS, H. MALIN, ANKLESARIA, PERVIN, HEALD, ALISON E. · 2010 · The Journal of Rheumatology
Cited by 114

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Objective.: To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. Methods.: In this phase 1/2 randomized study, adults with persistent moderate or severe inflammation in a target joint, being treated with or without systemic anti-TNF therapy, received a single IA injection of either rAAV2-TNFR:Fc (1 × 10 11 , 1 × 10 12 , or 1 × 10 13 DNase-resistant particles/ml joint volume) or placebo, followed by open-label rAAV2-TNFR:Fc 12–30 weeks later, depending on when the target joint met predetermined criteria for reinjection. Results.: 127 subjects received the first injection of blinded study drug; 95 subjects received open-label rAAV2-TNFR:Fc. Administration site reactions, consisting of transient mild to moderate increases in tenderness and swelling of the injected joint, occurred after 23/191 (12%) rAAV2-TNFR:Fc injections and were dose-dependent. Rates of other adverse events were not dose-dependent. Notable serious adverse events (SAE) included culture-negative septic arthritis in a subject receiving leflunomide and fatal disseminated histoplasmosis considered unrelated to rAAV2-TNFR:Fc in a subject receiving adalimumab. In the phase 2 portion of the study, a 30% decrease in target joint global visual analog scale was observed in 21/50 (42%) rAAV2-TNFR:Fc subjects and 3/16 (19%) placebo subjects 12 weeks after first injection (p = 0.14). Conclusion.: IA rAAV2-TNFR:Fc resulted in administration site reactions after 12% of injections. A fatal SAE, disseminated histoplasmosis, was considered not related to study agent. Patient-reported outcome measures of clinical response showed greater improvement in treated patients than placebo patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3899/jrheum.090817

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 114

Metadata

Authors
MEASE, P. J., WEI, N., FUDMAN, E. J., KIVITZ, A. J., SCHECHTMAN, J., TRAPP, R. G., HOBBS, K. F., GREENWALD, M., HOU, A., BOOKBINDER, S. A., GRAHAM, G. E., WIESENHUTTER, C. W., WILLIS, L., RUDERMAN, E. M., FORSTOT, J. Z., MARICIC, M. J., DAO, K. H., PRITCHARD, C. H., FISKE, D. N., BURCH, F. X., PRUPAS, H. M., ANKLESARIA, P., & HEALD, A. E.
Venue
The Journal of Rheumatology
Published
2009-12-23
Volume
37
Issue
4
Pages
692-703
ISSN
  • 0315-162X (ISSN-L)
  • 1499-2752
OpenAlex
W2096900091
Cited by
114
References
4
FWCI
6.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study. https://app.cochat.ai/papers/10.3899/jrheum.090817
The paper
MEASE, P. J., WEI, N., FUDMAN, E. J., KIVITZ, A. J., SCHECHTMAN, J., TRAPP, R. G., HOBBS, K. F., GREENWALD, M., HOU, A., BOOKBINDER, S. A., GRAHAM, G. E., WIESENHUTTER, C. W., WILLIS, L., RUDERMAN, E. M., FORSTOT, J. Z., MARICIC, M. J., DAO, K. H., PRITCHARD, C. H., FISKE, D. N., . . . HEALD, A. E. (2010). Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.090817

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.